Evidence map›Paper›PMID 34163120›Full record

ArticleWorld journal of gastroenterology2021

Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.

Ligia Yukie Sassaki, Sender J Miszputen, Roberto Luiz Kaiser Junior, Wilson R Catapani, Mauro Bafutto, António S Scotton, Cyrla Zaltman, Julio Pinheiro Baima, Hagata S Ramos, Mikaell Alexandre Gouvea Faria and 19 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 16 institutions in 2 countries.

Ligia Yukie SassakiDepartment of Internal Medicine, Botucatu Medical School at Sao Paulo State University (UNESP), Botucatu 18618-687, São Paulo, Brazil. ligiasassaki@gmail.com.
Sender J MiszputenDepartment of Gastroenterology, Escola Paulista de Medicina, Sao Paulo, São Paulo 18618-687, São Paulo, Brazil.
Roberto Luiz Kaiser JuniorDepartment of Proctology, Kaiser Day Hospital, São Jose do Rio Preto 15015-110, São Paulo, Brazil.
Wilson R CatapaniDepartment of Gastroenterology, Faculdade de Medicina do ABC, Santo Andre 09060-870, São Paulo, Brazil.
Mauro BafuttoDepartment of Gastroenterology, Faculdade de Medicina, Goiania 74535-170, Goiás, Brazil.
António S ScottonDepartment of Gastroenterology, CMIP Centro Mineiro de Pesquisa, Juiz de Fora 36010-570, Minas Gerais, Brazil.
Cyrla ZaltmanDepartment of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Rio de Janeiro, Brazil.
Julio Pinheiro BaimaDepartment of Internal Medicine, Botucatu Medical School at Sao Paulo State University (UNESP), Botucatu 18618-687, São Paulo, Brazil.
Hagata S RamosDepartment of Gastroenterology, Escola Paulista de Medicina, São Paulo 04023-900, São Paulo, Brazil.
Mikaell Alexandre Gouvea FariaDepartment of Proctology, Kaiser Day Hospital, São Jose do Rio Preto 15015-110, São Paulo, Brazil.
Carolina D GonçalvesDepartment of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Rio de Janeiro, Brazil.
Isabella Miranda GuimaraesDepartment of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro 21941-913, Rio de Janeiro, Brazil.
Cristina FloresHospital de Clínicas de Porto Alegre, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Rio Grande do Sul, Brazil.
Heda M B S AmaranteHospital de Clinicas da Universidade Federal do Paraná, Hospital de Clinicas da Universidade Federal do Paraná, Curitiba Paraná, Paraná, Brazil.
Rodrigo Bremer NonesGastroenterology Department, Hospital Nossa Senhora das Graças, Curitiba 80810-040, Paraná, Brazil.
José Miguel Luz ParenteDepartment of General Medicine, Universidade Federal do Piauí, Teresina 64049-550, Piauí, Brazil.
Murilo Moura LimaGastroenterology, Hospital Universitario da Universidade Federal do Piaui, Teresina 64049-550, Piauí, Brazil.
Júlio Maria ChebliDepartment of Medicine, University Hospital of Federal University of Juiz de Fora, Juiz de Fora, Juiz de Fora 36036-247, Minas Gerais, Brazil.
Maria de Lourdes Abreu FerrariDepartment of Clinical Medicine, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil.
Julia F CamposDepartment of Clinical Medicine, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil.
Maria G P SannaDepartment of Clinical Medicine, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil.
Odery RamosHospital de Clinicas da Universidade Federal do Paraná, Hospital de Clinicas da Universidade Federal do Paraná, Curitiba 80060-900, Paraná, Brazil.
Rogério Serafim ParraDepartment of Surgery and Anatomy, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto 14048-900, São Paulo, Brazil.
Jose J R da RochaDepartment of Surgery and Anatomy, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto 14048-900, São Paulo, Brazil.
Omar FeresDepartment of Surgery and Anatomy, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto 14048-900, São Paulo, Brazil.
Marley R FeitosaDepartment of Surgery and Anatomy, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto 14048-900, São Paulo, Brazil.
Rosana Fusaro CaratinScientific Affairs, Takeda Pharmaceuticals Brazil, Sao Paulo 04709-011, Brazil.
Juliana Tosta SenraClinical Research, Takeda Pharmaceuticals, São Paulo 04709-011, São Paulo, Brazil.
Genoile Oliveira SantanaIBD Unit, Federal University of Bahia, Salvador 41150-000, Bahia, Brazil.
Universidade de Ribeirão Preto · BRUniversidade Federal de Minas Gerais · BRUniversidade Federal do Rio de Janeiro · BRAssociação Paulista de Medicina · BRHospital de Base · BRHospital de Clínicas Universidade Federal do Paraná · BRTakeda (Japan) · JPUniversidade Estadual Paulista (Unesp) · BRUniversidade Federal do Piauí · BRCentro Universitário Academia · BRFaculdade de Medicina do ABC · BRFundação de Apoio a Pesquisa do Estado de Goiás · BRHospital de Clínicas de Porto Alegre · BRHospital Nossa Senhora das Graças · BRUniversidade Federal da Bahia · BRUniversidade Federal de Juiz de Fora · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCrohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBDs) with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden, especially in patients with moderate-to-severe disease. The Real-world Data of Moderate-to-Severe Inflammatory Bowel Disease in Brazil (RISE BR) study was a noninterventional study designed to evaluate disease control, treatment patterns, disease burden and health-related quality of life in patients with moderate-to-severe active IBD. We report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or CD.

aimTo describe the 12-mo disease evolution and treatment patterns among patients with active moderate-to-severe IBD in Brazil.

methodsThis was a prospective, noninterventional study of adult patients with active Crohn's disease (CD: Harvey-Bradshaw Index ≥ 8, CD Activity Index ≥ 220), inadequate CD control (

resultsThe study included 118 CD and 36 UC patients, with mean ± SD ages of 43.3 ± 12.6 and 44.9 ± 16.5 years, respectively. The most frequent drug classes at index were biologics for CD (62.7%) and 5-aminosalicylate derivates for UC patients (91.7%). During follow-up, 65.3% of CD and 86.1% of UC patients initiated a new treatment at least once. Discontinuations/dose changes occurred in 68.1% of CD patients [median 2.0 (IQR: 2-5)] and 94.3% of UC patients [median 4.0 (IQR: 3-7)]. On average, CD and UC patients had 4.4 ± 2.6 and 5.0 ± 3.3 outpatient visits, respectively. The median time to first mild or no activity was 319 (IQR: 239-358) d for CD and 320 (IQR: 288-358) d for UC patients. At 9-12 mo, 22.0% of CD and 20.0% of UC patients had active disease.

conclusionAlthough a marked proportion of active IBD patients achieved disease control within one year, the considerable time to achieve this outcome represents an unmet medical need of the current standard of care in a Brazilian real-world setting.

Indexed as

Colitis, UlcerativeInflammatory Bowel DiseasesAdultBrazilHumansMiddle AgedProspective StudiesQuality of LifeCrohn’s diseaseInflammatory bowel diseasesProspective studyUlcerative colitis

Identifiers

PMID34163120
PMCPMC8218356
OpenAlexW3173719539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.